Abstract:
Introduction. Benign prostatic hyperplasia and chronic prostatitis are the most common conditions in men, the frequency
of which varies with age. Chronic prostatitis (infectious or inflammatory) has a frequency of 8-35% in patients aged 20-50
years, reaching a maximum of 60-70% in those aged over 50 years.
Materials and methods. Materials for the study served the medical literature regarding benign prostatic hyperplasia
and chronic inflammation, published in the local and international scientific journals. Scientific databases like Cochrane
Library, Medline, Scopus, Medicus, NCBI, PubMed, Google Scholar were used to find the necessary articles. Research methods
– analysis, synthesis, systematization, and description.
Results. After analyzing the available data, a review of the literature was conducted which highlighted both the strong and
weak points of the historical medical approaches to addressing benign prostatic hyperplasia, as well as the ontogenetics
and anatomical characteristics of the prostate gland. This included examining the incidence rates, concepts of causation
and development, principles of diagnosis and classification of benign prostatic hyperplasia. The review also revealed the
pros and cons of using mini-invasive treatment strategies versus traditional transvesical approaches in treating this condition, as well as the ongoing and significant socioeconomic impact in underdeveloped countries.
Conclusions. There remains the issue of reducing intra- and post-operative complications after benign prostatic hyperplasia surgery, especially a voluminous one, which imposes itself as a very critical problem in the development of an effective
treatment strategy. For the first time, a problem was described by assessing the particularities of some biochemical criteria
at local surgical site and in blood serum, histological - at the level of nodular prostatic hyperplasia and at the border of the
surgical site. This requires a complex correlational study to assess the biochemical, histological and immunohistochemical
parameters, including the evaluation of the associations or coexistence of benign prostatic hyperplasia and chronic prostatitis.
